Today: 28 February 2026
Subscribe
Browse Category

NASDAQ:CDTX 24 September 2025 - 9 January 2026

Merck (MRK) stock today: $32 billion Revolution talks and CDC vaccine shift put Feb. 3 in play

Merck (MRK) stock today: $32 billion Revolution talks and CDC vaccine shift put Feb. 3 in play

Merck shares rose 0.4% to $111.41 Friday after a report said it is in talks to buy Revolution Medicines for $28–32 billion. Revolution shares jumped 16% in extended trading. Merck just completed a $221.50-per-share tender offer for Cidara Therapeutics and said the deal will raise 2026 R&D expense by $9 billion. Analysts warned U.S. vaccine policy changes could cut Merck revenue by $2 billion annually.
9 January 2026
···
Merck stock climbs on Wolfe upgrade as Cidara deal closes and Gardasil questions linger

Merck stock climbs on Wolfe upgrade as Cidara deal closes and Gardasil questions linger

Merck shares rose 1.5% to $110.20 after Wolfe Research upgraded the stock and set a $135 price target. Merck completed its $221.50-per-share tender offer for Cidara and flagged a $9 billion R&D charge for 2026. Investors watched fallout from a U.S. shift to a single-dose HPV vaccine recommendation ahead of Merck’s Feb. 3 results.
8 January 2026
····
Merck (MRK) stock slips after-hours as CDC backs one-dose HPV shot; Cidara deal closes

Merck (MRK) stock slips after-hours as CDC backs one-dose HPV shot; Cidara deal closes

Merck shares slipped 0.2% in after-hours trading after U.S. health officials cut HPV vaccine guidance to one dose, raising concerns over Gardasil sales. Analysts warned the change could reduce 2026 Gardasil revenue by up to $630 million. Merck also completed its $9.2 billion Cidara acquisition and set Feb. 3 for quarterly results.
8 January 2026
····
Merck stock slips after Cidara tender offer; $9 billion R&D hit and HPV schedule shift in focus

Merck stock slips after Cidara tender offer; $9 billion R&D hit and HPV schedule shift in focus

Merck shares slipped 0.3% to $108.59 after it completed its tender offer for Cidara Therapeutics and expects to finalize the $9.2 billion acquisition later Wednesday. The deal will add about $9 billion to 2026 R&D expenses and reduce earnings per share by 30 cents in the first year. Merck also began a Phase 3 lung-cancer trial of calderasib with Keytruda QLEX. U.S. officials updated HPV and rotavirus vaccine guidance this week.
7 January 2026
·····
Merck stock starts 2026 higher as Cidara tender-offer deadline hits next week

Merck stock starts 2026 higher as Cidara tender-offer deadline hits next week

Merck shares rose 1.2% to $106.45 Friday after Nasdaq set Jan. 6 as the expiration for its $9.2 billion cash tender offer for Cidara Therapeutics. Cidara shares will be halted after Jan. 6 and suspended Jan. 8 if the merger closes as planned. Merck’s move snapped a three-day losing streak, leaving the stock just below its 52-week high. About 10 million shares traded, below the 50-day average.
3 January 2026
···
Merck Stock (MRK) News and Forecasts: FDA Fast-Track Vouchers, TrumpRx Pricing Deal, and Cidara Acquisition in Focus Ahead of the Next Market Session

Merck Stock (MRK) News and Forecasts: FDA Fast-Track Vouchers, TrumpRx Pricing Deal, and Cidara Acquisition in Focus Ahead of the Next Market Session

U.S. stock markets are closed for the weekend as of 2:34 a.m. ET Saturday. Merck last traded near $106.78, up 0.33%. The company is in focus after joining TrumpRx-linked drug pricing deals and announcing 70% discounts on diabetes drugs for U.S. consumers. Trading volume remains thin following a flat Friday session.
27 December 2025
···
Cidara Therapeutics (CDTX) Surges on Accelerated Flu Drug Trial – Key Updates for Investors

Merck’s $9.2 Billion Bid Sends Cidara Therapeutics (CDTX) Soaring 105% on November 14, 2025

Merck said it will acquire Cidara Therapeutics for $221.50 per share in cash, valuing the deal at about $9.2 billion. The offer represents a 109% premium to Cidara’s last closing price and sent CDTX shares up more than 100%. Both companies’ boards approved the deal, which is expected to close in early 2026 pending regulatory clearance. Merck aims to secure Cidara’s lead flu-prevention drug, CD388.
14 November 2025
··
5 Most Interesting Nasdaq Stocks Today (November 14, 2025): AMAT, CDTX, NVDA, AAPL & TSLA

5 Most Interesting Nasdaq Stocks Today (November 14, 2025): AMAT, CDTX, NVDA, AAPL & TSLA

The Nasdaq Composite fell about 1.5% by late morning, marking a fifth straight decline as tech stocks sold off and hopes for a near-term Fed rate cut faded. Applied Materials dropped up to 6% after warning of weaker China demand despite strong earnings. Cidara Therapeutics more than doubled after Merck agreed to acquire it for $9.2 billion. Chip and EV shares led losses.
14 November 2025
······
Merck to Buy Cidara Therapeutics for $9.2 Billion in Bold Bet on Long‑Acting Flu Prevention

Merck to Buy Cidara Therapeutics for $9.2 Billion in Bold Bet on Long‑Acting Flu Prevention

Merck will acquire Cidara Therapeutics for about $9.2 billion, paying $221.50 per share in cash—a 109% premium to Cidara’s last close. The deal gives Merck rights to CD388, a Phase 3 long-acting flu prevention drug. Cidara shares doubled in pre-market trading. The transaction is expected to close in Q1 2026, pending approvals.
14 November 2025
···
Cidara Therapeutics (CDTX) Surges on Accelerated Flu Drug Trial – Key Updates for Investors

Cidara Therapeutics (NASDAQ: CDTX) 2025 Investment Analysis – Will This Anti‑Flu Innovator Keep Soaring?

Cidara Therapeutics’ stock rose 279% year-to-date, closing at $101.99 on Oct. 3, 2025, up from $26.88 at the start of the year. The company’s CD388 drug showed 76% protection against flu in a Phase 2b trial. BARDA awarded up to $339 million in October for manufacturing and clinical development. As of June, Cidara held $516.9 million in cash.
4 October 2025
··
Cidara Therapeutics (CDTX) Surges on Accelerated Flu Drug Trial – Key Updates for Investors

Cidara Therapeutics (CDTX) Stock Soars After $339M BARDA Flu-Drug Deal – Is CD388 the Next Big Flu-Fighter?

Cidara shares jumped 5.7% to $104.13 Friday morning, nearing a 52-week high after winning a BARDA award worth up to $339 million for its flu drug CD388. The stock is up over 200% year-to-date, with analysts raising price targets as high as $173. Cidara reported $516.9 million in cash and a Q2 net loss of $25.7 million. Short interest stands at 11.3% of float.
3 October 2025
··
Cidara Therapeutics (CDTX) Surges on Accelerated Flu Drug Trial – Key Updates for Investors

Cidara Therapeutics (CDTX) Surges on Accelerated Flu Drug Trial – Key Updates for Investors

Cidara Therapeutics shares surged over 20% to near $88 on Sept. 24, 2025, after the FDA allowed it to accelerate Phase 3 trials for its flu drug CD388 by six months and expand the eligible population to over 100 million adults. The stock is up 173% year-to-date. Cidara raised $402.5 million in June, bringing cash reserves to $516.9 million, and now owns 100% of CD388 after ending a Janssen partnership.
24 September 2025
·
Go toTop